Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma

NCT03770416 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03770416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03770416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2019
Completion date
February 10, 2025
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system b-cell non-hodgkin lymphoma, recurrent central nervous system lymphoma, refractory central nervous system lymphoma